Skip to main content

Advertisement

SpringerLink
Log in

Biotech's wellspring: a survey of the health of the private sector

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

An examination of the private biotech industry reveals shrinking financial resources and higher hurdles to obtain funding, but new models are evolving to meet the challenge.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Global venture funding of private biotech companies, 2001–2011.
Figure 2: Venture capital investment for biotechnology therapeutic companies.
Figure 3: Top university patent assignees.

Author information

Authors and Affiliations

  1. Brady Huggett is Nature Biotechnology's Business Editor.,

    Brady Huggett

Authors
  1. Brady Huggett
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Supplementary Text and Figures

Supplementary Figure 1 and Supplementary Tables 1-8 (XLSX 63 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huggett, B. Biotech's wellspring: a survey of the health of the private sector. Nat Biotechnol 30, 395–400 (2012). https://doi.org/10.1038/nbt.2209

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2209

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation